Proto Labs Q3 revenue beats on CNC machining growth

By Reuters News


Overview

  • Digital manufacturing firm's Q3 revenue rose 14% yr/yr, beating analyst expectations

  • Adjusted EPS for Q3 rose 33% yr/yr and beat analyst expectations

  • Company raised full-year 2026 revenue growth guidance to 10%-11%


Outlook

  • Company raises full-year 2026 revenue growth guidance to 10%-11% from 8%-10%

  • Company expects Q4 2026 revenue between $143 mln and $151 mln

  • Company sees Q4 2026 GAAP EPS of $0.28-$0.36 and non-GAAP EPS of $0.46-$0.54


Result Drivers

  • CNC MACHINING GROWTH - Co said CNC machining revenue rose 16.4% yr/yr

  • INJECTION MOLDING DEMAND - Injection molding revenue increased 12.5% yr/yr, per co

  • 3D PRINTING UPTICK - 3D printing revenue rose 11.4% yr/yr, according to co


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Beat

$154.32 mln

$149.04 mln (5 Analysts)

Q3 Adjusted EPS

Beat

$0.63

$0.60 (5 Analysts)

Q3 Net Income

$11.76 mln

Q3 Gross Profit

$68.66 mln

Q3 Operating Expenses

$54.22 mln

Q3 Operating Income

$14.44 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the industrial machinery & equipment peer group is "buy"

  • Wall Street's median 12-month price target for Proto Labs, Inc. is $102.00, about 12.2% above its October 28 closing price of $90.91

  • The stock recently traded at 38 times the next 12-month earnings vs. a P/E of 39 three months ago


Reuters Recommended Reads

  • Oct 27 - Illinois Tool Works Inc beats Q3 EPS estimates, raises 2026 outlook

  • Oct 28 - Flowserve Q3 adjusted profit beats estimates on bookings growth, market expansion

  • Oct 28 - IDEX Q3 sales beat on increased volumes


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.